Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623460
What this trial is testing

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

Who this might be right for
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Stuthi Perimbeti 30
Not applicableLooking for participantsNCT07677267
What this trial is testing

Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Novartis Pharmaceuticals 1,067
Testing effectiveness (Phase 2)Ended earlyNCT03207867
What this trial is testing

NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Who this might be right for
NSCLC, Non Small Cell Lung CancerRCC, Renal Cell CancerPancreatic Cancer+7 more
Novartis Pharmaceuticals 315
Testing effectiveness (Phase 2)Study completedNCT03093428
What this trial is testing

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute 45
Testing effectiveness (Phase 2)Study completedNCT02121639
What this trial is testing

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

Who this might be right for
Prostate Cancer
University Hospital Southampton NHS Foundation Trust 160
Testing effectiveness (Phase 2)Study completedNCT01881867
What this trial is testing

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+1 more
Fred Hutchinson Cancer Center 54
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795268
What this trial is testing

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Norroy Bioscience Co., LTD 600
Early research (Phase 1)Study completedNCT04666129
What this trial is testing

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Sensitive Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc. 48
Testing effectiveness (Phase 2)Looking for participantsNCT07354594
What this trial is testing

External Beam and Radioligand Radiotherapy for mCRPC

Who this might be right for
Prostate Cancer Metastatic Castration-Resistant
Centre hospitalier de l'Université de Montréal (CHUM) 120
Testing effectiveness (Phase 2)Study completedNCT00942578
What this trial is testing

Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
National Cancer Institute (NCI) 63
Not applicableStudy completedNCT04516161
What this trial is testing

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Bayer 1,180
Early research (Phase 1)Study completedNCT03751436
What this trial is testing

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+6 more
Roswell Park Cancer Institute 10
Testing effectiveness (Phase 2)Study completedNCT02130700
What this trial is testing

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 17
Early research (Phase 1)Ended earlyNCT02963051
What this trial is testing

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Daniel George, MD 9
Not applicableLooking for participantsNCT06514521
What this trial is testing

Post Marketing Study on Pluvicto in Korea

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 278
Early research (Phase 1)Active Not RecruitingNCT04846478
What this trial is testing

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Who this might be right for
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 35
Testing effectiveness (Phase 2)Ended earlyNCT02146833
What this trial is testing

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Who this might be right for
Prostate Cancer
Karyopharm Therapeutics Inc 20
Not applicableLooking for participantsNCT07096999
What this trial is testing

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate Carcinoma
University of Michigan Rogel Cancer Center 60
Early research (Phase 1)Looking for participantsNCT07570979
What this trial is testing

Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Looking for participantsNCT07192120
What this trial is testing

MHB048C in Patients With Advanced Solid Tumors

Who this might be right for
mCRPC (Metastatic Castration-resistant Prostate Cancer)Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd 200
Next Page